• Late Breaking Results from ADJOIN LTE with Max and Marissa: Leaping into Lebrikizumab at EADV

  • 2024/11/04
  • 再生時間: 32 分
  • ポッドキャスト

Late Breaking Results from ADJOIN LTE with Max and Marissa: Leaping into Lebrikizumab at EADV

  • サマリー

  • Unlocking the Secrets of Clear Skin (and Soggy Shoes) in Amsterdam! 🌧️👟✨

    Ready to revolutionize your approach to atopic dermatitis? 🤔

    Join us on the latest episode of the Skin and Joints podcast, live from the EADV in Amsterdam! 🇳🇱

    Dr. Marissa Joseph and Dr. Max Sauder, braved the Dutch downpours to bring you exclusive insights into lebrikizumab—the new kid on the block that's making waves 🌊 in eczema treatment.

    Discover how this IL-13 inhibitor is changing the game 🎯 with its long-term efficacy, flexible dosing schedules, and impressive safety profile. 📊 We'll dive deep into the ADJOIN study's three-year data, discuss where lebrikizumab fits into the current treatment landscape for their respective practices 🩺, and explore how it could be a game-changer for your patients..

    🗺️Get a taste of our guests' Amsterdam adventures—from waterlogged wanderings 🚶‍♀️🌧️ to culinary delights 🍽️ Plus, find out why Max might be shopping for a princess dress 👗 before the next conference 🏰🎢

    🎙️ Tune in and get ready to see atopic dermatitis treatment in a whole new light! 💡

    Learning Objectives:

    1. Understand the mechanism of action of lebrikizumab in treating atopic dermatitis, focusing on its role as an IL-13 inhibitor 🧬.
    2. Analyze the long-term efficacy and safety data from the ADjoin study, emphasizing the durability of lebrikizumab over a three-year period 📈.
    3. Compare the dosing regimens (biweekly vs. monthly) of lebrikizumab and their implications for patient adherence and treatment outcomes 📆.
    4. Evaluate how lebrikizumab fits into current clinical practice for atopic dermatitis, considering patient preferences and the spectrum of available therapies 🩺.
    5. Recognize the importance of expanding therapeutic options in atopic dermatitis management and how to personalized patient care 🎯.

    ABOUT DR.MARISSA JOSEPH

    Dermatologist, Toronto, ON

    Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

    Dr. Marissa Joseph is a board certified Pediatrician and Dermatologist after completing Pediatric training at the Hospital For Sick Children, following with a Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health.

    Dr. Joseph is full time academic faculty at the Unee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativersity of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education. Dr. Joseph is the Medical Director of the Ricky Kaniva; genodermatoses, and equity, diversity and inclusivity.

    About Dr.Maxwell Sauder MD, FRCPCDermatologist | Toronto

    Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

    Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

    Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions.

    Epsode supported by an Independent Medical Educational Grant from Lilly.

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca

    📻www.skinandjoints.ca

    ✉️info@skinandjoints.ca

    続きを読む 一部表示

あらすじ・解説

Unlocking the Secrets of Clear Skin (and Soggy Shoes) in Amsterdam! 🌧️👟✨

Ready to revolutionize your approach to atopic dermatitis? 🤔

Join us on the latest episode of the Skin and Joints podcast, live from the EADV in Amsterdam! 🇳🇱

Dr. Marissa Joseph and Dr. Max Sauder, braved the Dutch downpours to bring you exclusive insights into lebrikizumab—the new kid on the block that's making waves 🌊 in eczema treatment.

Discover how this IL-13 inhibitor is changing the game 🎯 with its long-term efficacy, flexible dosing schedules, and impressive safety profile. 📊 We'll dive deep into the ADJOIN study's three-year data, discuss where lebrikizumab fits into the current treatment landscape for their respective practices 🩺, and explore how it could be a game-changer for your patients..

🗺️Get a taste of our guests' Amsterdam adventures—from waterlogged wanderings 🚶‍♀️🌧️ to culinary delights 🍽️ Plus, find out why Max might be shopping for a princess dress 👗 before the next conference 🏰🎢

🎙️ Tune in and get ready to see atopic dermatitis treatment in a whole new light! 💡

Learning Objectives:

  1. Understand the mechanism of action of lebrikizumab in treating atopic dermatitis, focusing on its role as an IL-13 inhibitor 🧬.
  2. Analyze the long-term efficacy and safety data from the ADjoin study, emphasizing the durability of lebrikizumab over a three-year period 📈.
  3. Compare the dosing regimens (biweekly vs. monthly) of lebrikizumab and their implications for patient adherence and treatment outcomes 📆.
  4. Evaluate how lebrikizumab fits into current clinical practice for atopic dermatitis, considering patient preferences and the spectrum of available therapies 🩺.
  5. Recognize the importance of expanding therapeutic options in atopic dermatitis management and how to personalized patient care 🎯.

ABOUT DR.MARISSA JOSEPH

Dermatologist, Toronto, ON

Marissa Joseph, MSc, MD, FRCPC ( Pediatrics), FRCPC ( Dermatology)

Dr. Marissa Joseph is a board certified Pediatrician and Dermatologist after completing Pediatric training at the Hospital For Sick Children, following with a Dermatology residency at the University of Toronto. She completed a MSc in Community Health at the Dalla Lana School of Public Health.

Dr. Joseph is full time academic faculty at the Unee Schachter Dermatology Centre at Women's College Hospital. She also works at the Hospital For Sick Children where she manages children with complex dermatologic disease in outpatient and inpatient settings, as well as a pediatric laser treatment program. Dr. Joseph enjoys her diverse practice in general adult, pediatric and surgical dermatology. Her clinical and research interests include inflammatory skin disorders such as psoriasis, atopic dermatitis, and hidradenitis suppurativersity of Toronto. She has received and has been nominated for teaching awards in both undergraduate and postgraduate medical education. Dr. Joseph is the Medical Director of the Ricky Kaniva; genodermatoses, and equity, diversity and inclusivity.

About Dr.Maxwell Sauder MD, FRCPCDermatologist | Toronto

Dr. Maxwell Sauder is a board-certified dermatologist with additional fellowship training. He earned his Doctor of Medicine at McMaster University and completed a residency in dermatology at The University of Ottawa. He completed fellowship training in Cutaneous Oncology at Harvard Medical School. He is a former instructor in dermatology at Harvard Medical School.

Dr. Sauder is currently an assistant professor at the University of Toronto. He is an onco-dermatologist at Princess Margaret Cancer Centre. He also practices at Toronto Dermatology Centre where he is the research director and the director of the Pigmented Lesion Clinic.

Well published in numerous peer-reviewed journals, Dr. Sauder has also authored several book chapters, been referenced on www.uptodate.com, and has won numerous awards including the Partner’s President Prize at Harvard and the Royal College’s Detweiler Fellowship Award. His publications have covered topics such as eczema, patient education, aesthetic dermatology, sun safety, psoriasis, biologics, adverse drug reactions, hemangiomas, contact dermatitis, cutaneous oncology, and a host of complex medical dermatology conditions.

Epsode supported by an Independent Medical Educational Grant from Lilly.

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

📻www.skinandjoints.ca

✉️info@skinandjoints.ca

Late Breaking Results from ADJOIN LTE with Max and Marissa: Leaping into Lebrikizumab at EADVに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。